М.E. Sitdykova
Efficiency of biologically active compound "Prolit" in stone disease patients after extracorporeal shock wave lithotripsy
SUMMARY
Introduction in urology practice of extra-corporeal shock-wave lithotripsy (ESWL) has changed the way of stone disease treatment. Diminishing of side effects from ESWL is the important issue of modern urology. To figure out the possibility of biologically active compound (BAC) “Prolit” application in patients with nephrolithiasis, exposed to ESWL, we conducted the study of 42 patients with the stones of kidneys and ureters. It is revealed that prescribing of the “Prolit” to the urolithiasis patients before ESWL procedure assists renewal of the kidney blood circulation in more short time, to minimize the parenchymal damage in result of shock wave influence and to shorten a period between the sessions of lithotripsy.